NYSE · EVH

Evolent Health, Inc.

$3.54 -$0.68 (-16.11%) 1D Market open

Key Metrics

$474.67M
Market cap
P/E · TTM
$1.89B
Revenue · TTM
−$496.52M
Net income
EPS · TTM $-4.31
Dividend yield
Free cash flow
Beta · 1Y 0.82
EBITDA · TTM −$383.86M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 23
    The stock moved -16.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 23
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Mar 30
    From its Mar 2 high, the share price fell 39%.

    Peak close $3.58 on Mar 2; trough close $2.17 on Mar 30. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -39%
  • Feb 25
    The stock moved +22.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 25

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$474.67M
Enterprise value$1.31B
Shares outstanding112.5M
52-wk range$2.10 – $10.30
Avg volume · 20D1.6M
Net cash −$831.46M
Book value / share$3.44
IndustryServices-Management Services
ExchangeNYSE
About Evolent Health, Inc.
IPO dateJun 5, 2015
Employees4200

Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S0.25
P/FCF
EV/EBITDA
EV/Sales0.69
Graham №

Profitability

Gross
Operating -26.3%
Net -26.3%
FCF
ROE / ROIC -71.1% · -40.4%

Financial Health

Current ratio1.32
Quick ratio
Debt / equity2.46
Debt / EBITDA -2.54
Net cash −$831.46M
Working capital$120.78M

Cash Flow · TTM

Operating CF $33.29M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

-0.6
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings